Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Recurrent pregnancy loss (RPL) defined as 3 or more pregnancy losses affects approximately 3%
of couples trying to achieve parenthood. Most cases of RPL are unexplained and have no
effective treatment to improve the chance of a live birth. Exciting indications for using
Hydroxychloroquine (HCQ) include: Malaria profylaxis and treatment, systemic and discoid
lupus erythematosus (SLE) and rheumatoid athritis (RA). HCQ has been reported to have the
following properties (anti-thrombotic, vascular-protective, immunomodulatory, improving
glucose tolerance, lipid-lowering, and anti-infectious).
There is no data concerning the benefit of HCQ in RPL. Administration for other indications
provides extensive safety data during pregnancy.
This study has the potential to establish support for a new treatment option for unexplained
RPL.